Sciomics GmbH

General information
Sciomics GmbH
Karl-Landsteiner Str. 6
69151 Neckargemünd, Baden-Württemberg
Germany

Contact person: Christoph Schroeder, Founder and CEO
Company main phone: +49 (6223) 9689500
Website:  https://www.sciomics.de
Year founded:2013
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:German Cancer Research Center (DKFZ)
Corporate description / mission:
Sciomics, a biotechnology company which offers proteomic and post-translational modification profiling platform enables true progress in precision medicine. The company is currently focused on operative Acute Kidney Injury (AKI) as well as a project on the prediction of a severe COVID-19 disease course. The company provides scientific high-content protein profiling services based on antibody microarray platform. The analysis is based on either our fixed-contentarray portfolio (scioDiscover, scioCyto, scioCD) or customized antibody arrays.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - R&D Services
Subsector:
  • Analytical services
  • CRO (Contract Research Organization)
  • Diagnostic services
  • Proteomics
  • Screening
Primary therapeutic areas:
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
  • Research on contract basis
  • Service company
Customer segments:
  • Large biotech & big pharma
  • Large medtech
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Description of products:
Services:
© 2026 Biotechgate by Venture Valuation
X